Gilead Sciences GILD Valuation Implications of Expanded Kymera Therapeutics Collaboration and Kymeras FDA Fast Track Designation FSBC Five Star posts a 68 percent Q4 2025 EPS beat as its stock slips 052 percent in todays session Bright Horiz BFAM Stock Bear Call Spread Steady Decline 20260427